News | March 03, 2024
Briefs: SMS Pharmaceuticals and Vimta Labs
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
BHL will undertake the development and supply of these molecules
The plant will drive pharmaceutical innovation in the Northeastern India
Suven Pharmaceuticals’ API and forumulations facilities complete USFDA inspection successfully
iSolveSM information on demand is the result of our focus on customer relationship
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Microdosing has emerged as a key trend in the pharmaceutical and nutritional markets
The Aptivate Champion Run witnessed an enthusiastic participation of over 4,000 Mumbaikars
The R&D centre is mainly dedicated to the Process R&D of New Chemical Entities (NCE) development projects
Subscribe To Our Newsletter & Stay Updated
